Diane Jelinek

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
  2. pmc Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies
    R C Tschumper
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 3:e112. 2013
  3. pmc Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells
    Xiaosheng Wu
    Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 5:e15549. 2010
  4. pmc Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression
    Albert Gutierrez
    Department of Immunology, Mayo Graduate School, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e26056. 2011
  5. pmc Induction of malignant plasma cell proliferation by eosinophils
    Tina W Wong
    Department of Immunology, Mayo Clinic, Rochester, Minneapolis, USA
    PLoS ONE 8:e70554. 2013
  6. pmc Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing
    Renee C Tschumper
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Oncotarget 3:502-13. 2012
  7. ncbi request reprint Identification of a global gene expression signature of B-chronic lymphocytic leukemia
    Diane F Jelinek
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Res 1:346-61. 2003
  8. pmc Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression
    D F Jelinek
    Department of Immunology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    J Clin Invest 99:447-56. 1997
  9. ncbi request reprint Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors
    Diane F Jelinek
    Department of Immunology, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Curr Dir Autoimmun 8:266-88. 2005
  10. ncbi request reprint Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
    Anne J Novak
    Department of Immunology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905
    Blood 103:689-94. 2004

Collaborators

Detail Information

Publications65

  1. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
    ....
  2. pmc Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies
    R C Tschumper
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 3:e112. 2013
    ..The PCR findings were confirmed by immunofluorescence for HC and LC expression. Clonally related HC-dissimilar/LC-matched DMGs may occur often and defines a new subtype of MG that may serve as a tool for studies of disease pathogenesis...
  3. pmc Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells
    Xiaosheng Wu
    Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 5:e15549. 2010
    ..In consideration of the critical role that CD4+ T cells play in inducing the SHR process, our data suggest a novel role for CD4+ T cells in the tumor suppression of GC/post-GC B cells...
  4. pmc Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression
    Albert Gutierrez
    Department of Immunology, Mayo Graduate School, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e26056. 2011
    ..These data support the notion that CLL can differentiate into ISC and that this triggers decreased leukemic cell survival secondary to the down regulation of LEF-1 and decreased Wnt pathway activation...
  5. pmc Induction of malignant plasma cell proliferation by eosinophils
    Tina W Wong
    Department of Immunology, Mayo Clinic, Rochester, Minneapolis, USA
    PLoS ONE 8:e70554. 2013
    ..Taken together, our study demonstrates for the first time a role for Eos in the pathology of MM and suggests that therapeutic strategies targeting these cells may be beneficial. ..
  6. pmc Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing
    Renee C Tschumper
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Oncotarget 3:502-13. 2012
    ..This study demonstrates the power and potential weaknesses of in-depth sequencing as a tool to thoroughly investigate the phylogeny of malignant PCs in MM and the IGHV repertoire of normal BMPCs...
  7. ncbi request reprint Identification of a global gene expression signature of B-chronic lymphocytic leukemia
    Diane F Jelinek
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Res 1:346-61. 2003
    ..Finally, we identified a group of 31 genes that distinguish between low (Rai stage 0) and high (Rai stage 4) risk patients, suggesting that there may also be a gene expression signature that associates with disease progression...
  8. pmc Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression
    D F Jelinek
    Department of Immunology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    J Clin Invest 99:447-56. 1997
    ..Identification of these mechanisms may allow development of agents that are more universally effective than IFN-alpha...
  9. ncbi request reprint Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors
    Diane F Jelinek
    Department of Immunology, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Curr Dir Autoimmun 8:266-88. 2005
    ..In this article, we will review the spectrum of human B lineage malignancies and discuss current evidence supporting a role for BLyS and APRIL in fueling the growth and survival of specific B cell malignancies...
  10. ncbi request reprint Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
    Anne J Novak
    Department of Immunology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905
    Blood 103:689-94. 2004
    ..Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets...
  11. ncbi request reprint A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth
    D F Jelinek
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 159:487-96. 1997
    ..In summary, these studies suggest that IGFs may play an important role in multiple myeloma by virtue of their ability to directly stimulate tumor cell growth as well as modulate the magnitude of IL-6-driven growth...
  12. ncbi request reprint Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia
    D F Jelinek
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Br J Haematol 115:854-61. 2001
    ..These data strongly encourage the study of these biological markers as they relate to disease heterogeneity in B-CLL...
  13. ncbi request reprint Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach
    J D French
    Dept of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 16:1189-96. 2002
    ..Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells...
  14. ncbi request reprint Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth
    J D French
    Department of Immunology, Mayo Graduate and Medical School, Mayo Clinic, Rochester, Minnesota, USA
    Acta Oncol 39:777-81. 2000
    ..This combined approach has the potential to assess the relative importance of several signalling events in myeloma cell growth control and identify IL-6 responsive genes in this malignancy...
  15. ncbi request reprint Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines
    Carlton W Thomas
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    J Pharmacol Exp Ther 312:537-45. 2005
    ..These results therefore provide a previously unrecognized molecular mechanism for the immunosuppressive properties of thiopurine antimetabolite drugs...
  16. doi request reprint Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
    Tait Shanafelt
    Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Leuk Lymphoma 51:2222-9. 2010
    ..No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL...
  17. ncbi request reprint Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:616-23. 2004
    ..We conclude that inhibition of survivin expression is an attractive therapeutic strategy in aggressive non-Hodgkin's lymphomas, and that combining survivin ASO with rituximab may enhance the efficacy of this approach...
  18. ncbi request reprint VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance
    Y K Lee
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 19:513-23. 2005
    ..Thus, a VEGF-VEGF receptor pathway in CLL B cells can be linked to activation of STAT proteins that are able to enhance their apoptotic resistance...
  19. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  20. ncbi request reprint B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
    N E Kay
    Department of Medicine, Division of Hematology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 16:911-9. 2002
    ....
  21. ncbi request reprint Sharpening spots: correcting for bleedover in cDNA array images
    Terry Therneau
    Department of Health Sciences Research, Mayo Foundation, Rochester, MN 55905, USA
    Math Biosci 176:1-15. 2002
    ..The sharpened images look like a set of donuts, which concurs with our knowledge of the spotting process. Oversharpened images are actually useful as well, in locating the centers of each spot...
  22. ncbi request reprint Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells
    B K Arendt
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Leukemia 16:2142-7. 2002
    ....
  23. ncbi request reprint ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype
    J C Nolz
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
    Leukemia 19:1018-24. 2005
    ..These results provide new insight into normal human B-cell biology as well as provide clues about the transformed cell in B-CLL...
  24. ncbi request reprint CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation
    B T Pittner
    Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
    Leukemia 19:2264-72. 2005
    ..Taken together, these data suggest that CD38 is a marker of a more recently activated CLL B cell. This in turn may explain the biological and clinical differences between CD38-positive type B-CLL and CD38-negative type B-CLL...
  25. ncbi request reprint Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome
    S M Ansell
    Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:720-6. 2001
    ..This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL...
  26. ncbi request reprint The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection
    D K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Antisense Nucleic Acid Drug Dev 12:411-8. 2002
    ..Thus, our studies illustrate the striking dependence of dsRNA-mediated gene silencing in some cells on the methods of dsRNA transfection...
  27. pmc Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 111:785-9. 2008
    ..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
  28. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  29. ncbi request reprint Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 356:2582-90. 2007
    ..Prognostic factors for the progression and outcome of this disease are unclear...
  30. ncbi request reprint Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells
    Jaime R Darce
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, 200 First Street Southwest, Rochester, MN 55905, USA
    J Immunol 178:5612-22. 2007
    ..Taken together, these data define a complex role for BAFF in humoral immune responses and show for the first time that BAFF can also play an inhibitory role in B cell differentiation...
  31. ncbi request reprint Regulated expression of BAFF-binding receptors during human B cell differentiation
    Jaime R Darce
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester MN 55905, USA
    J Immunol 179:7276-86. 2007
    ..Collectively, our data suggest that the BBR profile may serve as a footprint of the activation history and stage of differentiation of normal human B cells...
  32. pmc Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients
    Renee C Tschumper
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 118:306-15. 2008
    ..In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL...
  33. pmc MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
    Tait D Shanafelt
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:1458-61. 2008
    ..In contrast, CD38 predicted TTT (p=0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold...
  34. pmc Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 113:2110-8. 2008
    ..In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab...
  35. doi request reprint CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 140:537-46. 2008
    ..Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases. Clinical testing of anti-CD49d therapy in CLL appears warranted...
  36. pmc The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:615-21. 2008
    ..Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients...
  37. pmc Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    Shanique Palmer
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 141:607-14. 2008
    ..These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted...
  38. doi request reprint Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
    Tait D Shanafelt
    J Clin Oncol 26:e5-6. 2008
  39. pmc Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2
    Bonnie K Arendt
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 112:1931-41. 2008
    ..Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology...
  40. ncbi request reprint Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test
    Grzegorz S Nowakowski
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:449-53. 2007
    ..001). The percentage of smudge cells as a continuous variable correlated with overall survival (P=.04). The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL...
  41. ncbi request reprint Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
    ..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
  42. ncbi request reprint Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia
    Stephanie R Fink
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:253-62. 2005
    ..Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21...
  43. ncbi request reprint Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:2247-53. 2004
    ..In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma...
  44. ncbi request reprint VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
    Yean K Lee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:788-94. 2004
    ..Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death...
  45. ncbi request reprint A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells
    Denise K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Oncogene 23:1197-205. 2004
    ..These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system...
  46. ncbi request reprint IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
    Jun Won Lee
    Department of Medicine, Hematology Oncology Division, University of Pittsburgh, and Department of Vetrerans Affairs Medical Center, PA 15213, USA
    Blood 103:2308-15. 2004
    ..These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth...
  47. ncbi request reprint Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex
    Denise K Walters
    Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Oncogene 22:3598-607. 2003
    ..These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor...
  48. ncbi request reprint Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 121:287-95. 2003
    ..Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables...
  49. ncbi request reprint Transactivation of gp130 in myeloma cells
    Jena D French
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 170:3717-23. 2003
    ..Finally, transactivation of gp130 may be a common theme in myeloma cells, perhaps providing a mechanism for enhanced or qualitatively distinct cellular responses to specific stimuli...
  50. ncbi request reprint AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma
    Sun J Choi
    Department of Medicine Hematology Oncology, University of Pittsburgh, PA, USA
    Blood 101:3778-83. 2003
    ..The data suggest that strategies that enhance AML-1B expression or decrease AML-1A in MM cells may be beneficial therapeutically...
  51. ncbi request reprint Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival
    Anne J Novak
    Departments of Immunology, Pediatric and Adolescent Medicine, and Internal Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:2973-9. 2002
    ..Because these molecules are key regulators of B-cell homeostasis and tumor progression, leukemic cell autocrine expression of BLyS and APRIL may be playing an important role in the pathogenesis of this disease...
  52. ncbi request reprint MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
    Yasuo Oba
    Department of Medicine Hematology Oncology Division, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Exp Hematol 33:272-8. 2005
    ..Several chemokine receptors (CCR1, CCR5, and CCR9) mediate the effects of MIP-1alpha. In this study, we determined which of these mediates the effects of MIP-1alpha on human OCL formation and myeloma cells...
  53. ncbi request reprint Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS
    David R Barnidge
    Mayo Proteomics Research Center, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 819:33-9. 2005
    ..We show that despite the variance in SCX, capillary LC, and the data-dependent selection of precursor ions, an overlap of 64% between proteins identified in replicate runs was achieved for this system...
  54. ncbi request reprint Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
    J Clin Oncol 24:4634-41. 2006
    ..There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH...
  55. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  56. pmc A role for BLyS in the activation of innate immune cells
    Sook Kyung Chang
    Department of Immunology, Guggenheim 4, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 108:2687-94. 2006
    ..Moreover, this study may explain more clearly why high BLyS production is often correlated with certain inflammatory autoimmune diseases and B-lymphocyte malignancies...
  57. pmc Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
    Blood 108:2755-63. 2006
    ..Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue...
  58. ncbi request reprint Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
    ..Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease...
  59. ncbi request reprint A-Miz-ing BCL6
    Xiaosheng Wu
    Nat Immunol 6:964-6. 2005
  60. pmc Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents
    David R Barnidge
    Mayo Proteomics Research Center, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Proteome Res 4:1310-7. 2005
    ..These results demonstrate that stable isotope labeling and mass spectrometry can complement 2D gel electrophoresis and gene microarray technologies for identifying putative and perhaps unique prognostic markers in CLL...
  61. ncbi request reprint A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:1009-18. 2005
    ..These studies suggest that the IL-4R, on B-CLL cells, can serve as a unique molecular target for directing cytotoxic agents in the therapy of B-CLL...
  62. ncbi request reprint Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia
    Kami Maddocks-Christianson
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 139:398-404. 2007
    ..Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials...
  63. pmc B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation
    Sook Kyung Chang
    Department of Immunology, College of Medicine, Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 180:7394-403. 2008
    ..Collectively, our data suggest that BLyS may modulate adaptive immune cells indirectly by inducing DC maturation...
  64. ncbi request reprint Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
    Deborah A Bowen
    Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Leuk Lymphoma 48:2412-7. 2007
    ..Three-year survival was 41% (95% CI: 26 - 66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted...
  65. ncbi request reprint Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
    Michael R Grever
    Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 25:799-804. 2007
    ..1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome...

Research Grants16

  1. Role of the BCR in B Cell Chronic Lymphocytic Leukemia
    Diane Jelinek; Fiscal Year: 2009
    ..Through these studies, we aim to add novel insight into the etiology of this disease and are optimistic that this information can be used to devise timely novel therapeutic interventions. ..
  2. role of BLyS/April in Normal and Malignant Plasma Cells
    Diane Jelinek; Fiscal Year: 2007
    ..abstract_text> ..
  3. role of BLyS/April in Normal and Malignant Plasma Cells
    Diane Jelinek; Fiscal Year: 2006
    ..abstract_text> ..
  4. role of BLyS/April in Normal and Malignant Plasma Cells
    Diane Jelinek; Fiscal Year: 2005
    ..abstract_text> ..
  5. role of BLyS/April in Normal and Malignant Plasma Cells
    Diane Jelinek; Fiscal Year: 2004
    ..abstract_text> ..
  6. MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA
    Diane Jelinek; Fiscal Year: 2002
    ....
  7. MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA
    Diane Jelinek; Fiscal Year: 2001
    ....
  8. MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA
    Diane Jelinek; Fiscal Year: 2000
    ....
  9. MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMA
    Diane Jelinek; Fiscal Year: 1999
    ....
  10. Role of the BCR in B Cell Chronic Lymphocytic Leukemia
    Diane F Jelinek; Fiscal Year: 2010
    ..Through these studies, we aim to add novel insight into the etiology of this disease and are optimistic that this information can be used to devise timely novel therapeutic interventions. ..